Research Study for those with Early Alzheimer’s Disease

UVA Tracking #
Principal Investigator
Carol A Manning
Colleen Webber
Contact Email
Contact Phone
Official Trial Title
AUTONOMY: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
Study Description

The Neurology Department Memory Disorders Division seeks adults ages 55 to 80 with Early Alzheimer’s Disease for a research study. The purpose of the study is to test the safety and effectiveness of an investigational medicine.

You may be eligible for this study if You:
-Have a diagnosis of Mild Cognitive Impairment or Mild Alzheimer’s Disease
-Have an available study partner who knows you well and agrees to participate
-Are in good general health with stable medications

Study involves infusions of an investigational medication/placebo, neuropsychological testing, MRI scans, ECG’s, blood draws and PET scans. The study consists of a screening period (13 weeks), double-blind treatment period (up to 232 weeks), and a follow up period (13 weeks).

All study-related procedures provided at no cost.


You will receive compensation up to $54.00 for each successfully completed study visit and an additional 14.00 for your study partner for each successfully completed study visit.